DURECT (NASDAQ:DRRX – Get Rating) is scheduled to be releasing its earnings data after the market closes on Wednesday, May 4th. Analysts expect DURECT to post earnings of ($0.05) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
DURECT (NASDAQ:DRRX – Get Rating) last announced its quarterly earnings results on Monday, March 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.02. The firm had revenue of $7.30 million for the quarter, compared to analyst estimates of $2.40 million. DURECT had a negative return on equity of 52.37% and a negative net margin of 259.46%. During the same period last year, the firm posted ($0.04) earnings per share. On average, analysts expect DURECT to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of NASDAQ:DRRX opened at $0.45 on Monday. The firm’s fifty day moving average is $0.57 and its 200-day moving average is $0.82. DURECT has a 52 week low of $0.40 and a 52 week high of $1.93. The firm has a market cap of $102.46 million, a PE ratio of -2.81 and a beta of 1.31. The company has a debt-to-equity ratio of 0.36, a quick ratio of 7.94 and a current ratio of 8.13.
In other DURECT news, Director Judith J. Robertson acquired 200,000 shares of the business’s stock in a transaction on Monday, March 14th. The shares were acquired at an average price of $0.59 per share, with a total value of $118,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.60% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC bought a new position in shares of DURECT in the third quarter worth $29,000. BNP Paribas Arbitrage SA boosted its position in shares of DURECT by 330.0% in the third quarter. BNP Paribas Arbitrage SA now owns 43,064 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 33,050 shares during the period. Bank of America Corp DE grew its stake in DURECT by 186.2% during the fourth quarter. Bank of America Corp DE now owns 73,390 shares of the specialty pharmaceutical company’s stock valued at $73,000 after acquiring an additional 47,747 shares in the last quarter. Invesco Ltd. increased its holdings in DURECT by 25.7% during the 3rd quarter. Invesco Ltd. now owns 97,886 shares of the specialty pharmaceutical company’s stock worth $125,000 after acquiring an additional 20,009 shares during the period. Finally, Morgan Stanley raised its position in shares of DURECT by 274.4% in the second quarter. Morgan Stanley now owns 105,884 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 77,601 shares in the last quarter. 50.60% of the stock is currently owned by institutional investors and hedge funds.
About DURECT (Get Rating)
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
- Get a free copy of the StockNews.com research report on DURECT (DRRX)
- Enphase Energy Has a Sunny Future With Some Clouds in the Short Term
- Knight-Swift Transportation Stock is a Logistics Winner
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.